| Line Item | 2024-10-31 | Y/Y |
|---|---|---|
| Revenue | $4.98B | -8.9% |
| Cost of Revenue | $1.85B | -4.5% |
| R&D Expense | $919.0M | +4.2% |
| SG&A Expense | $1.40B | +6.7% |
| Operating Income | $833.0M | -38.7% |
| Interest Expense | $84.0M | +7.7% |
| Pre-tax Income | $865.0M | -36.3% |
| Income Tax | $251.0M | -16.3% |
| Net Income | $614.0M |
| Line Item | 2024-10-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.80B | -27.3% |
| Accounts Receivable | $857.0M | -4.8% |
| Inventory | $1.02B | +3.8% |
| Current Assets | $4.26B | -11.5% |
| Total Assets | $9.27B | +6.7% |
| Current Liabilities | $1.43B | -30.4% |
| Long-term Debt | $1.79B | -0.2% |
| Line Item | 2024-10-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.05B | -25.3% |
| Capital Expenditures | $154.0M | -21.4% |
| Investing Cash Flow | -$819.0M | -184.4% |
| Financing Cash Flow | -$913.0M | -32.9% |
| Free Cash Flow | $898.0M | -25.9% |
| -41.9% |
| EPS (Basic) | $3.53 | -40.7% |
| EPS (Diluted) | $3.51 | -40.6% |
| Total Liabilities |
| $4.16B |
| +3.4% |
| Stockholders' Equity | $5.11B | +9.7% |